Literature DB >> 24178953

Analysis of serum insulin growth factor-1 concentrations in localized osteosarcoma: a children's oncology group study.

Scott C Borinstein1, Donald A Barkauskas, Mark Bernstein, Allen Goorin, Richard Gorlick, Mark Krailo, Cindy L Schwartz, Leonard H Wexler, Jeffrey A Toretsky.   

Abstract

To investigate the role of insulin-like growth factor-1 (IGF-1), in localized osteosarcoma, serum levels of IGF-1, IGFBP-2, and IGFBP-3 were measured in 224 similarly treated, newly diagnosed patients. We demonstrated that younger patients had lower concentrations of IGF-1 and IGFBP-3 compared to older (P < 0.001) along with lower IGFBP-3:IGF-1 and IGFBP-2:IGF-1 ratios (P < 0.001). IGFBP-2 did not correlate with age (P = 0.16), yet IGFBP-2:IGF-1 ratios were higher in the younger population (P < 0.001). These findings show that older patients have higher concentrations of free IGF-1. None of IGF-1, IGFBP-2, nor IGFBP-3 concentrations were associated with event-free nor overall survival.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer biology; clinical trials; osteosarcoma

Mesh：

Substances：

Year:  2013        PMID： 24178953      PMCID： PMC3946315          DOI： 10.1002/pbc.24778

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  16 in total

1.  Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma.

Authors:  Yin-He Wang; Xiao-Dong Han; Yong Qiu; Jin Xiong; Yang Yu; Bin Wang; Ze-Zhang Zhu; Bang-Ping Qian; Yi-Xin Chen; Shou-Feng Wang; Hong-Fei Shi; Xu Sun
Journal:  J Surg Oncol       Date:  2011-08-22       Impact factor: 3.454

2.  Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group.

Authors:  Suman Malempati; Brenda Weigel; Ashish M Ingle; Charlotte H Ahern; Julie M Carroll; Charles T Roberts; Joel M Reid; Stephen Schmechel; Stephan D Voss; Steven Y Cho; Helen X Chen; Mark D Krailo; Peter C Adamson; Susan M Blaney
Journal:  J Clin Oncol       Date:  2011-12-19       Impact factor: 44.544

3.  Reference values for IGF-I throughout childhood and adolescence: a model that accounts simultaneously for the effect of gender, age, and puberty.

Authors:  C Löfqvist; E Andersson; L Gelander; S Rosberg; W F Blum; K Albertsson Wikland
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

4.  Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas.

Authors:  Irène Asmane; Emmanuel Watkin; Laurent Alberti; Adeline Duc; Perrine Marec-Berard; Isabelle Ray-Coquard; Philippe Cassier; Anne-Valérie Decouvelaere; Dominique Ranchère; Jean-Emmanuel Kurtz; Jean-Pierre Bergerat; Jean-Yves Blay
Journal:  Eur J Cancer       Date:  2012-06-07       Impact factor: 9.162

5.  Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group.

Authors:  Katherine A Janeway; Donald A Barkauskas; Mark D Krailo; Paul A Meyers; Cindy L Schwartz; David H Ebb; Nita L Seibel; Holcombe E Grier; Richard Gorlick; Neyssa Marina
Journal:  Cancer       Date:  2012-01-17       Impact factor: 6.860

6.  Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth.

Authors:  C C Kappel; M C Velez-Yanguas; S Hirschfeld; L J Helman
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

7.  Insulin-like factor binding protein-3 promotes the G1 cell cycle arrest in several cancer cell lines.

Authors:  Chen Wu; Xiaobo Liu; Yuanyuan Wang; Huanna Tian; Yuanyuan Xie; Qinjian Li; Xiaokang Zhang; Fangming Liu
Journal:  Gene       Date:  2012-10-04       Impact factor: 3.688

8.  Serum levels of insulin-like growth factor (IGF)-I and IGF binding protein (IGFBP)-1 to -6 and their relationship to bone metabolism in osteoporosis patients.

Authors:  Peter M. Jehle; Klaus Schulten; Walter Schulz; Daniela R. Jehle; Sylvia Stracke; Burkhard Manfras; Bernhard O. Boehm; David J. Baylink; Subburaman Mohan
Journal:  Eur J Intern Med       Date:  2003-02       Impact factor: 4.487

9.  Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels.

Authors:  Patrick J Mansky; David J Liewehr; Seth M Steinberg; George P Chrousos; Nilo A Avila; Lauren Long; Donna Bernstein; Crystal L Mackall; Douglas S Hawkins; Lee J Helman
Journal:  J Pediatr Hematol Oncol       Date:  2002 Aug-Sep       Impact factor: 1.289

10.  Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program.

Authors:  E Anders Kolb; Richard Gorlick; Peter J Houghton; Christopher L Morton; Richard Lock; Hernan Carol; C Patrick Reynolds; John M Maris; Stephen T Keir; Catherine A Billups; Malcolm A Smith
Journal:  Pediatr Blood Cancer       Date:  2008-06       Impact factor: 3.167
View more
  3 in total

1.  A summary of the osteosarcoma banking efforts: a report from the Children's Oncology Group and the QuadW Foundation.

Authors:  Jason Glover; Mark Krailo; Tanya Tello; Neyssa Marina; Katherine Janeway; Don Barkauskas; Timothy M Fan; Richard Gorlick; Chand Khanna
Journal:  Pediatr Blood Cancer       Date:  2014-12-08       Impact factor: 3.167

Review 2.  Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies.

Authors:  James J Morrow; Chand Khanna
Journal:  Crit Rev Oncog       Date:  2015

3.  Osteosarcoma enters a post genomic era with in silico opportunities: Generation of the High Dimensional Database for facilitating sarcoma biology research: A report from the Children's Oncology Group and the QuadW Foundation.

Authors:  Jason Glover; Tsz-Kwong Man; Donald A Barkauskas; David Hall; Tanya Tello; Mary Beth Sullivan; Richard Gorlick; Katherine Janeway; Holcombe Grier; Ching Lau; Jeffrey A Toretsky; Scott C Borinstein; Chand Khanna; Timothy M Fan
Journal:  PLoS One       Date:  2017-07-21       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.